QT Vascular gets green light for four patents
MEDICAL supplies firm QT Vascular Ltd on Wednesday said the United States Patent and Trademark Office has issued allowance letters of four fundamental patents key to its unique portfolio of specialty balloons for the treatment of vascular disease in coronary and peripheral vessels.
The Catalist-listed firm said three of the patents cover the group's flagship platform, Chocolate®, while the fourth patent covers its Glider™ family of products.
Dr Eitan Konstantino, QT Vascular's CEO, said: "To receive four key patents allowances within a short span of time is truly an exceptional experience for a start-up company. We remain focused on the execution of our operational milestones and especially the drug coating programme."
QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, based in Pleasanton, California.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UBS weighs synthetic risk transfer amid capital boost proposals
Oil settles higher on supply concerns in the Mid-East, economic woes subdue gains
S-Reits falter as investors weigh possibility of zero rate cuts in 2024
CapitaLand Investment posts total revenue of S$650 million for Q1
Europe: Stoxx 600 logs best day in three months as banks shine
US: Stocks rally after strong tech results